David  Aviezer has 25 years of experience in senior biotechnology executive management, advancing products from early-stage research up to their approval by FDA and into commercialization. From 2002 through 2014 he served as President and Chief Executive Officer of Protalix BioTherapeutics, leading it to public listing on the New York Stock Exchange and to receiving  FDA approval of its drug for Gauchers disease, a rare genetic disorder. Prof. Aviezer has hands on experience in creating strategic partnerships and research agreements as well as raising capital in the private and public markets. Before joining Protalix, Prof. Aviezer served as General Manager of ProChon Biotech/CTI, a biotechnology company focused on rare growth disorders. Prior to that, he was a visiting scientist at the Medical Research Division of Cyanamid -Wyeth, now Pfizer,  in Pearl River, New York. He holds a PhD in Molecular Biology and Biochemistry from the Weizmann Institute of Science and an MBA from the Bar-Ilan University Business School.

Liora earned her PhD (summa cum laude) in molecular and cellular biology from Bar-Ilan University, Israel. She has a twenty-year track record of successfully translating scientific concepts into late-stage clinical products, especially in dermatology and orphan indications, as well as extensive experience constructing regulatory strategies for the FDA. Before coming to Kamari, Liora served as the Head of Innovation and Research and Development at NeuroDerm, a Mitsubishi Tanabe pharmaceutical company.

Mr. Yarkoni, has been a finance executive and consultant for over 15 years. He serves on the board of several companies, including Bio Meat Foodtech and Go.D.M Investments.

Prior joining Kamari , he served as CEO & CFO of several high-tech TASE companies and the M&A and integrations manager of IBM Israel.
He helped grow Storwize and managed its M&A into IBM ; Before this, he served as a manager at Deloitte. Mr. Yarkoni holds a BA in Business and accounting, and an MBA with a major in finance and capital market.

Before joining Kamari, Dr. Michel served as Vice President and program lead for solid tumors at Karyopharm, where she led solid tumors programs both from a strategic, medical and operational aspects. She has a twenty plus years’ experience in Pharmaceutical R&D, ranging from CRO to Biotech, with international experience in Medical and Clinical leadership positions, line and project management from early development to regulatory submission, with a track record of leading the preparation of 2 sNDA submissions in Sarcoma and Endometrial cancer. She is experienced in managing cross-functional, cross-cultural and geographically dispersed teams with ability to integrate scientific rationale and medical evidence with business objectives.

Dr. Michel, holds an MD from the Rappaport Faculty of Medicine, the Technion in Israel, with an active license to practice in Israel.

Dr. Almon joined Kamari Pharma Ltd. in July 2025 as its Chief Regulatory Officer.  Dr. Almon is a Biotech executive, former Chief Development Officer and SVP at Protalix Ltd, with over 25 years of extensive experience in global protein drug development including strategic planning, management, and execution of more than 10 global clinical programs ranging from pre-clinical through successful international registration Phase 3 studies with track record of 2 global Marketing Authorization Approvals (FDA & EMA).
Dr. Almon brings experience in global cross-functional teams management and ability to integrate scientific rationale and medical evidence with business objectives.
In addition, Dr. Almon has experience in the development of tissue-based therapies as well as a strong background and work experience in Intellectual Property.
Dr. Almon holds a Ph.D. and an M.Sc. in Molecular Biology of Cancer from the Weizmann Institute of Science, a B.Sc. from the Hebrew University and has carried out Post-Doctoral research at the Hebrew University in molecular biology and  genetic engineering.  Dr. Almon further completed Directors and Officers course at the Reichman University.